Cite
Myeloma clinical outcomes following the first wave of COVID‐19: results from the Thames Valley Cancer Alliance (UK).
MLA
Sharpley, Faye A., et al. “Myeloma Clinical Outcomes Following the First Wave of COVID‐19: Results from the Thames Valley Cancer Alliance (UK).” British Journal of Haematology, vol. 192, no. 6, Mar. 2021, pp. e136–39. EBSCOhost, https://doi.org/10.1111/bjh.17261.
APA
Sharpley, F. A., Larham, J., Haines, A., Djebbari, F., Tseu, B., Leary, H., Vallance, G., Panitsas, F., Ferguson, L., Roberts, P., Peniket, A., Gooding, S., Kothari, J., Moore, S., & Ramasamy, K. (2021). Myeloma clinical outcomes following the first wave of COVID‐19: results from the Thames Valley Cancer Alliance (UK). British Journal of Haematology, 192(6), e136–e139. https://doi.org/10.1111/bjh.17261
Chicago
Sharpley, Faye A., Jemma Larham, Angus Haines, Faouzi Djebbari, Bing Tseu, Heather Leary, Grant Vallance, et al. 2021. “Myeloma Clinical Outcomes Following the First Wave of COVID‐19: Results from the Thames Valley Cancer Alliance (UK).” British Journal of Haematology 192 (6): e136–39. doi:10.1111/bjh.17261.